Why Neogen Is On Investors’ Radar Today
Neogen (NEOG) is drawing attention after a period in which the stock shows a 4.7% move over the past month and a 105.98% total return over the past year, inviting closer scrutiny of what is driving sentiment.
See our latest analysis for Neogen.
The recent 10.12% 7 day share price return and 47.71% year to date share price return, alongside a 105.98% 1 year total shareholder return, point to momentum building despite weaker 3 and 5 year total shareholder returns.
If Neogen’s move has you rethinking where growth could come from next, this is a good moment to scan opportunities in healthcare focused AI. You could start with the 34 healthcare AI stocks.
With Neogen trading at US$10.34, sitting below an analyst price target of US$11.67 and an estimated intrinsic value gap of roughly 55%, you have to ask: is there genuine value here, or is the market already banking on future growth?
Most Popular Narrative: 11.4% Undervalued
Neogen’s most followed narrative places fair value at $11.67 per share, above the last close at $10.34, framing the current move as a potential discount.
Operational improvements and automation at the new Petrifilm production facility, alongside targeted actions to reduce inefficiencies in sample collection and inventory management, are expected to drive gross margin and EBITDA margin improvements over the coming quarters as execution stabilizes and overhead absorption rates improve.
Curious what has to change in Neogen’s margins to support that higher value, and how flat revenue assumptions still produce meaningful earnings power? The narrative leans heavily on future profitability, a richer earnings multiple, and the impact of the discount rate on today’s price tag, and it spells out the path in detail.
Result: Fair Value of $11.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story can quickly change if integration setbacks around Petrifilm persist, or if tariffs and divestiture-related costs keep pressuring margins longer than expected.
Find out about the key risks to this Neogen narrative.
Next Steps
With mixed sentiment running through this story, it makes sense to look at the underlying data yourself and act while the picture is still fresh, starting with the 1 key reward and 1 important warning sign.
Looking for more investment ideas?
If Neogen has sharpened your focus, do not stop here. Broaden your watchlist with other clear, data driven ideas before the next opportunity moves out of reach.
- Target stability first by reviewing companies highlighted in the 72 resilient stocks with low risk scores that may better match your comfort with volatility.
- Hunt for value by scanning the screener containing 24 high quality undiscovered gems and see which under followed names still line up with solid fundamentals.
- Prioritise financial strength by checking businesses in the solid balance sheet and fundamentals stocks screener (40 results) that combine resilience with room for future decisions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com